Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/55931

TitleLipid-based Nanocarriers for siRNA Delivery: Challenges, Strategies and the Lessons Learned from the DODAX: MO Liposomal System
Author(s)Oliveira, Ana C. N.
Fernandes, Joana
Gonçalves, Anabela
Andreia C. Gomes
Real Oliveira, M. Elisabete C.D.
Gomes, Andreia C
KeywordsCationic liposomes
monoolein
siRNA delivery
DODAB
DODAC
PEGylation
Issue date2019
PublisherBentham Science Publishers
JournalCurrent Drug Targets
Abstract(s)The possibility of using the RNA interference (RNAi) mechanisms in gene therapy was one of the scientific breakthroughs of the last century. Despite the extraordinary therapeutic potential of this approach, the need for an efficient gene carrier is hampering the translation of the RNAi technology to the clinical setting. Although a diversity of nanocarriers has been described, liposomes continue to be one of the most attractive siRNA vehicles due to their relatively low toxicity, facilitated siRNA complexation, high transfection efficiency and enhanced pharmacokinetic properties. This review focuses on RNAi as a therapeutic approach, the challenges to its application, namely the nucleic acids’ delivery process, and current strategies to improve therapeutic efficacy. Additionally, lipid-based nanocarriers are described, and lessons learned from the relation between biophysical properties and biological performance of the dioctadecyldimethylammonium:monoolein (DODAX: MO) system are explored. Liposomes show great potential as siRNA delivery systems, being safe nanocarriers to protect nucleic acids in circulation, extend their half-life time, target specific cells and reduce off-target effects. Nevertheless, several issues related to delivery must be overcome before RNAi therapies reach their full potential, namely target-cell specificity and endosomal escape. Understanding the relationship between biophysical properties and biological performance is an essential step in the gene therapy field.
TypeArticle
URIhttp://hdl.handle.net/1822/55931
DOI10.2174/1389450119666180703145410
ISSN1389-4501
e-ISSN1873-5592
Publisher versionhttp://www.eurekaselect.com/163461/article
Peer-Reviewedyes
AccessOpen access
Appears in Collections:CDF - FAMO - Capítulos de livros/Book chapters

Files in This Item:
File Description SizeFormat 
Oliveira et al. Current Durug Targets 2018.pdf3,35 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID